HAIFA, Israel, June 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Pluristem's CEO and its Project Innovation Research Manager will be delivering two different presentations during Israel's largest biotechnology conference, the 12th Annual IATI-BioMed Conference June 10th through 12th, 2013 in Tel Aviv.
Zami Aberman, Pluristem's Chairman and CEO, has been invited to speak at a satellite symposium on June 11th entitled "Haifa -Life sciences: innovation and excellence at its best". Mr. Aberman will present details of the company, as Pluristem exemplifies the type of success story in the life sciences created at Haifa's MATAM Advanced Technology Park. Accompanying Mr. Aberman to the podium will be Mr. Yona Yahav, Mayor of the City of Haifa and Professor Dan Shechtman, Nobel Laureate in Chemistry, Technion - Israel Institute of Technology, who will be the keynote speaker.
Additionally, on June 11th, Eytan Abraham PhD, Project Innovation Research Manager at Pluristem, will give a lecture entitled "Systemic Therapeutic Effect of Placental Expanded Cells (PLX) Following Local Administration in Hind Limb Ischemia Model," and will present data illustrating that the local intramuscular (IM) administration of PLX-PAD cells can produce a systemic effect in this animal model.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we discuss that local intramuscular (IM) administration of PLX-PAD cells can produce a systemic effect in this animal model we are using forward-looking statements. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.